Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5600 on 2017-11-17

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2001-01-08

BUY
Abbott Labs (ABT-N)
Getting into acquisitions. Had to restructure. Moving from a value to a growth stock
biotechnology/pharmaceutical
Noah Blackstein, B.A., CFA

Prtf Mngr (Goodman & Company, Investment Counsel), Dynamic Funds

Price: $42.563
Owned: Unknown

2001-12-10

BUY
Abbott Labs (ABT-N)
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $55.500
Owned: Unknown

2003-09-03

BUY
Abbott Labs (ABT-N)
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
biotechnology/pharmaceutical
Brad Willock

Vice President and Senior Portfolio Manager, RBC Asset Management

Price: $41.750
Owned: Unknown

2004-04-30

BUY
Abbott Labs (ABT-N)
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
biotechnology/pharmaceutical
David King

Portfolio Manager, New Value Fund, Putnam Investments

Price: $44.020
Owned: Unknown

2004-05-21

TOP PICK
Abbott Labs (ABT-N)
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
biotechnology/pharmaceutical
Harvey Eisen

Chairman, Bedford Oaks Partners

Price: $40.000
Owned: Yes

2005-08-25

DON'T BUY
Abbott Labs (ABT-N)
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $45.110
Owned: No

2007-08-29

BUY
Abbott Labs (ABT-N)
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
biotechnology/pharmaceutical
Norman Levine

Managing Director, Portfolio Management Corp

Price: $51.490
Owned: Unknown

2008-11-21

TOP PICK
Abbott Labs (ABT-N)
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
biotechnology/pharmaceutical
Walter Gerasimowicz

Chairman and CEO, Meditron Asset Management

Price: $51.520
Owned: Yes

2009-07-08

BUY
Abbott Labs (ABT-N)
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $46.310
Owned: No

2010-01-13

TOP PICK
Abbott Labs (ABT-N)
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $55.290
Owned: Yes

2010-01-14

COMMENT
Abbott Labs (ABT-N)
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
biotechnology/pharmaceutical
David Baskin

President, Baskin Wealth Management

Price: $55.350
Owned: Unknown

2010-04-14

BUY
Abbott Labs (ABT-N)
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
biotechnology/pharmaceutical
Don Lato

President, Padlock Investment Management

Price: $52.310
Owned: Yes

2010-04-26

TOP PICK
Abbott Labs (ABT-N)
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $50.370
Owned: Yes

2010-05-12

BUY
Abbott Labs (ABT-N)
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $49.150
Owned: Unknown

2010-05-27

DON'T BUY
Abbott Labs (ABT-N)
The model price is $48.13, a 2% upside only. Fully priced.
biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $47.870
Owned: No

Showing 1 to 15 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.